Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial (vol 41, pg 3329, 2023)

被引：0
|
作者：
Iwase, Takuji
Saji, Shigehira
Iijima, Kotaro
Higaki, Kenji
Ohtani, Shoichiro
Sato, Yasuyuki
Hozumi, Yasuo
Hasegawa, Yoshie
Yanagita, Yasuhiro
Takei, Hiroyuki
Tanaka, Maki
Masuoka, Hideji
Tanabe, Masahiko
Egawa, Chiyomi
Komoike, Yoshifumi
Nakamura, Toshitaka
Ohtsu, Hiroshi
Mukai, Hirofumi
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 23期
关键词：
D O I：
10.1200/JCO.23.01230
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：3962 / 3962
页数：1
相关论文
共 50 条
  • [41] Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
    Mary E. Peterson
    Supportive Care in Cancer, 2013, 21 : 2341 - 2349
  • [42] Randomized open-label phase III multicenter trial comparing TAXOL®/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer
    Pluzzanska, A
    Jassem, J
    Jelic, S
    Gorbunova, V
    Mrsic-Krmpotic, Z
    Berzins, J
    Nagykálnai, T
    Wigler, N
    Renard, J
    Statuch, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S314 - S314
  • [43] Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
    Hurvitz, Sara A.
    Bardia, Aditya
    Quiroga, Vanesa
    Park, Yeon Hee
    Blancas, Isabel
    Alonso-Romero, Jose Luis
    Vasiliev, Aleksandr
    Adamchuk, Hryhoriy
    Salgado, Marcelo
    Yardley, Denise A.
    Berzoy, Oleksandr
    Zamora-Aunon, Pilar
    Chan, David
    Spera, Gonzalo
    Xue, Cloris
    Ferreira, Erika
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Lopez-Valverde, Vanesa
    Steinseifer, Jutta
    Fernando, Tharu M.
    Moore, Heather M.
    LANCET ONCOLOGY, 2023, 24 (09): : 1029 - 1041
  • [44] A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer
    OC Freedman
    E Amir
    G Dranitsaris
    M Dowsett
    DEC Cole
    H Kahn
    F O'Malley
    S Verma
    M Clemons
    Breast Cancer Research, 11
  • [45] Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancer-A CLIPP program INCA in collaboration with GINECO group.
    Heudel, Pierre-Etienne
    Frenel, Jean-Sebastien
    Dalban, Cecile
    Bazan, Fernando
    Joly, Florence
    Arnaud, Antoine
    Abdeddaim, Cyril
    Chevalier, Annick
    Augereau, Paule
    Pautier, Patricia
    Chakiba, Camille
    You, Benoit
    Lecomte, Laurence Lancry
    Garin, Gwenaelle
    MArcel, Virginie
    Diaz, Jean-Jacques
    Treilleux, Isabelle
    Perol, David
    Fabbro, Michel
    Ray-Coquard, Isabelle Laure
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer
    Freedman, O. C.
    Amir, E.
    Dranitsaris, G.
    Dowsett, M.
    Cole, D. E. C.
    Kahn, H.
    O'Malley, F.
    Verma, S.
    Clemons, M.
    BREAST CANCER RESEARCH, 2009, 11 : S20 - S20
  • [47] A Phase III, Multicenter, Collaborative, Open-Label Clinical Trial of Sildenafil in Japanese Patients With Pulmonary Arterial Hypertension (vol 75, pg 677, 2011)
    Satoh, Tohru
    Saji, Tsutomu
    Watanabe, Hiroshi
    Ogawa, Satoshi
    Takehara, Kazuhiko
    Tanabe, Nobuhiro
    Yamada, Norikazu
    Yao, Atsushi
    Miyaji, Katsumasa
    Nakanishi, Norifumi
    Suzuki, Yumiko
    Fujiwara, Tadami
    Kuriyama, Takayuki
    CIRCULATION JOURNAL, 2011, 75 (07) : 1779 - 1779
  • [48] First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer
    Tjan-Heijnen, V. C.
    Van Hellemond, I. E.
    Peer, P. G.
    Swinkels, A. C.
    Smorenburg, C. H.
    Van der Sangen, M.
    Kroep, J. R.
    De Graaf, H.
    Honkoop, A. H.
    Erdkamp, F.
    Van den Berkmortel, F. W.
    Kitzen, J. J.
    De Boer, M.
    De Roos, W. K.
    Linn, S. C.
    Imholz, A. L.
    Seynaeve, C.
    CANCER RESEARCH, 2017, 77
  • [49] Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trialaEuro
    Zdenkowski, N.
    Forbes, J. F.
    Boyle, F. M.
    Kannourakis, G.
    Gill, P. G.
    Bayliss, E.
    Saunders, C.
    Della-Fiorentina, S.
    Kling, N.
    Campbell, I.
    Mann, G. B.
    Coates, A. S.
    Gebski, V.
    Davies, L.
    Thornton, R.
    Reaby, L.
    Cuzick, J.
    Green, M.
    ANNALS OF ONCOLOGY, 2016, 27 (05) : 806 - 812
  • [50] Adjuvant ovarian suppression plus aromatase inhibitor or tamoxifen for hormone receptor-positive breast cancer in women younger than 35 (ASPAIT): A multicenter randomized clinical trial
    Shan, Zhen
    Shao, Nan
    Yuan, Zhongyu
    Chen, Qianjun
    Zhang, Anqin
    Wang, Kun
    Zhang, Ailing
    Cai, Li
    Song, Yuhua
    Yao, Herui
    Ma, Hongmin
    Huang, Heng
    Li, Jianwen
    Zhang, Yuanqi
    Zhang, Lehong
    Zhong, Jincai
    Liu, Hui
    Wu, Zhiyong
    Zhao, Li
    Ling, Feihai
    Yang, Weixiong
    Zhuo, Rui
    Song, Xiangyang
    Lin, Ying
    CANCER RESEARCH, 2020, 80 (04)
12345